drugset / Trial / NCT06309485
Phase 2 Study of WGI-0301 for Advanced HCC
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
Timeline
- Start
- 2024-07-31
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | WGI-0301 | Antisense oligonucleotide | — | Intravenous |